Literature DB >> 35192418

Piquing our interest: Insights into the role of PEAK3 in signaling and disease.

Michael D Paul1, Hayarpi Torosyan1, Natalia Jura1,2.   

Abstract

Pseudokinases are critical signaling hubs that are increasingly appreciated as important disease targets. In this issue of Science Signaling, Hou et al. bring new insights into the signaling mechanisms of the pseudokinase PEAK3 by characterizing its epidermal growth factor-dependent interactome and demonstrating oncogenic effects of PEAK3 overexpression.

Entities:  

Mesh：

Year:  2022        PMID： 35192418      PMCID： PMC9288111          DOI： 10.1126/scisignal.abm9396

Source DB:  PubMed          Journal:  Sci Signal        ISSN： 1945-0877            Impact factor:   9.517


  10 in total

1.  Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and cancer progression [corrected].

Authors:  Yingchun Wang; Jonathan A Kelber; Hop S Tran Cao; Greg T Cantin; Rui Lin; Wei Wang; Sharmeela Kaushal; Jeanne M Bristow; Thomas S Edgington; Robert M Hoffman; Michael Bouvet; John R Yates; Richard L Klemke
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

2.  Homo- and Heterotypic Association Regulates Signaling by the SgK269/PEAK1 and SgK223 Pseudokinases.

Authors:  Ling Liu; Yu Wei Phua; Rachel S Lee; Xiuquan Ma; Yiping Jenkins; Karel Novy; Emily S Humphrey; Howard Chan; Robert Shearer; Poh Chee Ong; Weiwen Dai; Darren N Saunders; Isabelle S Lucet; Roger J Daly
Journal:  J Biol Chem       Date:  2016-08-16       Impact factor: 5.157

3.  Dimerization of the Pragmin Pseudo-Kinase Regulates Protein Tyrosine Phosphorylation.

Authors:  Céline Lecointre; Valérie Simon; Clément Kerneur; Frédéric Allemand; Aurélie Fournet; Ingrid Montarras; Jean-Luc Pons; Muriel Gelin; Constance Brignatz; Serge Urbach; Gilles Labesse; Serge Roche
Journal:  Structure       Date:  2018-03-01       Impact factor: 5.006

Review 4.  The PEAK family of pseudokinases, their role in cell signalling and cancer.

Authors:  Onisha Patel; Michael J Roy; James M Murphy; Isabelle S Lucet
Journal:  FEBS J       Date:  2019-11-06       Impact factor: 5.542

5.  PEAK3/C19orf35 pseudokinase, a new NFK3 kinase family member, inhibits CrkII through dimerization.

Authors:  Mitchell L Lopez; Megan Lo; Jennifer E Kung; Małgorzata Dudkiewicz; Gwendolyn M Jang; John Von Dollen; Jeffrey R Johnson; Nevan J Krogan; Krzysztof Pawłowski; Natalia Jura
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-16       Impact factor: 11.205

6.  Distinct PEAK3 interactors and outputs expand the signaling potential of the PEAK pseudokinase family.

Authors:  Jianmei Hou; Elizabeth V Nguyen; Minglyanna Surudoi; Michael J Roy; Onisha Patel; Isabelle S Lucet; Xiuquan Ma; Roger J Daly
Journal:  Sci Signal       Date:  2022-02-22       Impact factor: 8.192

7.  The crystal structure of pseudokinase PEAK1 (Sugen kinase 269) reveals an unusual catalytic cleft and a novel mode of kinase fold dimerization.

Authors:  Byung Hak Ha; Titus J Boggon
Journal:  J Biol Chem       Date:  2017-12-06       Impact factor: 5.157

8.  Temporal regulation of EGF signalling networks by the scaffold protein Shc1.

Authors:  Yong Zheng; Cunjie Zhang; David R Croucher; Mohamed A Soliman; Nicole St-Denis; Adrian Pasculescu; Lorne Taylor; Stephen A Tate; W Rod Hardy; Karen Colwill; Anna Yue Dai; Rick Bagshaw; James W Dennis; Anne-Claude Gingras; Roger J Daly; Tony Pawson
Journal:  Nature       Date:  2013-07-11       Impact factor: 49.962

9.  C-terminal Src kinase-mediated EPIYA phosphorylation of Pragmin creates a feed-forward C-terminal Src kinase activation loop that promotes cell motility.

Authors:  Yoshie Senda; Naoko Murata-Kamiya; Masanori Hatakeyama
Journal:  Cancer Sci       Date:  2016-06-13       Impact factor: 6.716

10.  SHED-Dependent Oncogenic Signaling of the PEAK3 Pseudo-Kinase.

Authors:  Youcef Ounoughene; Elise Fourgous; Yvan Boublik; Estelle Saland; Nathan Guiraud; Christian Recher; Serge Urbach; Philippe Fort; Jean-Emmanuel Sarry; Didier Fesquet; Serge Roche
Journal:  Cancers (Basel)       Date:  2021-12-17       Impact factor: 6.639
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.